A Busy Month in the Business of microRNA


June 29thAlnylam Obtains Approvals to Initiate Phase I Study with ALN-TTR01 in Patients with TTR-Mediated Amyloidosis (ATTR)

June 29thMirna Therapeutics Publishes Data Demonstrating In Vivo Proof of Concept for miR-34a microRNA Replacement Therapy in Cancer

June 28thReimbursement for Rosetta Genomics’ miRview™ mets Test Now Available in Israel Through World’s Second Largest HMO

June 28thAlnylam Scientists and Collaborators Publish Research in Nature Chemical Biology on a Novel Mechanism for Regulation of Gene Expression with Anti-Gene RNAs (agRNAs)

June 23rdSantaris Pharma A/S and miRagen Therapeutics, Inc. Form Strategic Alliance to Develop microRNA-Targeted Medicines for the Treatment of Cardiovascular Disease

June 23rdAlnylam Biotherapeutics Presents New Data on RNAi Applications in Biotherapeutics Manufacturing

June 22ndIsis and Alnylam Provide Update on Regulus’ Strategic Alliance with Sanofi-Aventis

June 22ndSanofi-Aventis and Regulus Therapeutics Form Major Strategic Alliance on microRNA Therapeutics

June 21stMirna Therapeutics Recommended for $10 Million Commercialization Award from the Cancer Prevention and Research Institute of Texas

June 17thAlnylam Secures Intellectual Property and Technology for RNAi Applications in Vaccine Research and Development

June 17thAlnylam Receives Notice of Allowance from United States Patent and Trademark Office for New Patent Broadly Covering RNAi Therapeutics that Target Mutated Genes

June 7thData Presented at ASCO 2010 by M. D. Anderson Researchers Demonstrate the ability of miRview™ mets to Identify the Most Likely Origin of Metastases in Cancer of Unknown Primary

June 3rdRosetta Genomics Establishes “Rosetta Green” as Majority-owned Subsidiary

Subscribe to the miRNA blog

Thank you for subscribing.

Something went wrong.

Related Posts

One Response

  1. Anonymous
    July 8, 2010

Add Comment